Effect of statin administration on the inflammatory response of monocytes in patients with atherosclerosis
- Authors: Kirichenko T.V.1,2, Yudina I.Y.3, Lukina M.V.3, Andrushchishina T.B.3, Zhivodernikov I.V.1, Markina Y.V.1
-
Affiliations:
- Petrovsky National Research Centre of Surgery
- Chazov National Medical Research Center of Cardiology
- I. Sechenov First Moscow State Medical University
- Issue: Vol 27, No 2 (2024)
- Pages: 259-266
- Section: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/1028-7221/article/view/263685
- DOI: https://doi.org/10.46235/1028-7221-16757-TEO
- ID: 263685
Cite item
Full Text
Abstract
Currently, statins are the main preparations of anti-atherosclerotic therapy due to a number of effects that reduce the progression of atherosclerosis, including anti-inflammatory effectiveness. The purpose of this study was to evaluate the inflammatory response of monocytes in patients with severe atherosclerosis during therapy with hydrophilic and lipophilic statins, as well as in patients with atherosclerosis not receiving lipid-lowering therapy. A total of 60 patients with severe atherosclerosis of the coronary arteries were included in the study in three groups: 1) receiving atovastatin therapy for at least 12 months before inclusion in the study, n = 20; 2) receiving rosuvastatin therapy for at least 12 months before inclusion in the study, n = 20; and 3) those who had not received statin therapy within a year before inclusion in the study, n = 20. The primary culture of monocytes from study participants was obtained by gradient centrifugation followed by immunomagnetic separation of CD14+ monocytes. The isolated cells were cultured for 7 days without stimulation and with pro-inflammatory stimulation using lipopolysaccharide (LPS). The level of basal, LPS-stimulated and re-stimulated secretion of TNFα and IL-1β was determined by enzyme immunoassay. Basal secretion of TNFα and IL-1β in patients receiving statins was lower than in patients who did not receive statins for a year; the secretion of both cytokines was significantly lower in the rosuvastatin group. LPS-stimulated TNFα secretion was significantly lower in the groups of patients receiving statins; IL-1β secretion was significantly lower in the atorvastatin and rosuvastatin groups compared to the group without statins. Re-stimulated IL-1β secretion did not differ significantly between groups; re-stimulated TNFα secretion was significantly lower in the rosuvastatin group compared to the atorvastatin and non-statin groups. Thus, the results of the study demonstrate the anti-inflammatory effectiveness of rosuvastatin, expressed in a decrease in the secretion of pro-inflammatory cytokines by cultured monocytes/macrophages of patients with severe coronary atherosclerosis.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
T. V. Kirichenko
Petrovsky National Research Centre of Surgery; Chazov National Medical Research Center of Cardiology
Author for correspondence.
Email: t-gorchakova@mail.ru
PhD (Medicine), Senior Research Associate, Laboratory of Cellular and Molecular Pathology of the Cardiovascular System; Research Associate, Laboratory of Medical Genetics
Russian Federation, Moscow; MoscowI. Yu. Yudina
I. Sechenov First Moscow State Medical University
Email: t-gorchakova@mail.ru
PhD (Medicine), Associate Professor, Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Sklifosovsky Institute of Clinical Medicine
Russian Federation, MoscowM. V. Lukina
I. Sechenov First Moscow State Medical University
Email: t-gorchakova@mail.ru
PhD (Medicine), Associate Professor, Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Sklifosovsky Institute of Clinical Medicine, Clinical Pharmacologist of the University Clinical Hospital No. 1
Russian Federation, MoscowT. B. Andrushchishina
I. Sechenov First Moscow State Medical University
Email: t-gorchakova@mail.ru
PhD (Medicine), Associate Professor, Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Sklifosovsky Institute of Clinical Medicine, Clinical Pharmacologist of the University Clinical Hospital No. 1
Russian Federation, MoscowI. V. Zhivodernikov
Petrovsky National Research Centre of Surgery
Email: t-gorchakova@mail.ru
PhD (Biology), Research Associate, Laboratory of Cellular and Molecular Pathology of the Cardiovascular System
Russian Federation, MoscowYu. V. Markina
Petrovsky National Research Centre of Surgery
Email: t-gorchakova@mail.ru
PhD (Medicine), Senior Research Associate, Laboratory of Cellular and Molecular Pathology of the Cardiovascular System
Russian Federation, MoscowReferences
- Hutton M., Frazer M., Lin A., Patel S., Misra A. New targets in atherosclerosis: vascular smooth muscle cell plasticity and macrophage polarity. Clin. Ther. 2023, Vol. 45, no. 11, pp. 1047-1054.
- Jinnouchi H., Guo L., Sakamoto A., Torii S., Sato Y., Cornelissen A., Kuntz S., Paek K.H., Fernandez R., Fuller D., Gadhoke N., Surve D., Romero M., Kolodgie F.D., Virmani R., Finn A.V. Diversity of macrophage phenotypes and responses in atherosclerosis. Cell. Mol. Life Sci., 2020, Vol. 77, no. 10, pp. 1919-1932.
- Kauerova S., Bartuskova H., Muffova B., Janousek L., Fronek J., Petras M., Poledne R., Kralova Lesna I. Statins directly influence the polarization of adipose tissue macrophages: a role in chronic inflammation. Biomedicines. 2021, Vol. 9, no. 2, 211. doi: 10.33
- Koushki K., Shahbaz S.K., Mashayekhi K., Sadeghi M., Zayeri Z.D., Taba M.Y., Banach M., Al-Rasadi K., Johnston T.P., Sahebkar A. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin. Rev. Allergy Immunol., 2021, Vol. 60, no. 2, pp. 175-199.
- Lin P., Ji H.H., Li Y.J., Guo S.D. Macrophage plasticity and atherosclerosis therapy. Front. Mol. Biosci., 2021, Vol. 8, 679797. doi: 10.3389/fmolb.2021.679797.
- Nikiforov N.G., Kirichenko T.V., Kubekina M.V., Chegodaev Y.S., Zhuravlev A.D., Ilchuk L.A., Nikolaeva M.A., Arefieva A.S., Popov M.A., Verkhova S.S., Bagheri Ekta M., Orekhov A.N. Macrophages derived from LPS-stimulated monocytes from individuals with subclinical atherosclerosis were characterized by increased pro-inflammatory activity. Cytokine, 2023, Vol. 172, 156411. doi: 10.1016/j.cyto.2023.156411.
- Oesterle A., Laufs U., Liao J.K. Pleiotropic effects of statins on the cardiovascular system. Circ. Res., 2017, Vol. 120, no. 1, pp. 229-243.
- Pedersen T.R. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am. J. Cardiovasc. Drugs, 2010, Vol. 10, no. 1, pp. 10-17.
- Ruleva N.Y., Radyukhina N.V., Zubkova E.S., Filatova A.Y., Aref’eva T.I. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase (statins) suppress differentiation and reduce LPS/IFNγ-induced cytokine production in human monocyte/macrophage culture. Bull. Exp. Biol. Med., 2020, Vol. 170, no. 2, p. 236-240.
- Singh M., McEvoy J.W., Khan S.U., Wood D.A., Graham I.M., Blumenthal R.S., Mishra A.K., Michos E.D. Comparison of transatlantic approaches to lipid management: The AHA/ACC/multisociety guidelines vs the ESC/EAS Guidelines. Mayo Clin. Proc., 2020, Vol. 95, no. 5, pp. 998-1014.
- Zhang T., Pang C., Xu M., Zhao Q., Hu Z., Jiang X., Guo M. The role of immune system in atherosclerosis: Molecular mechanisms, controversies, and future possibilities. Hum. Immunol., 2024, Vol. 85, no. 2, 110765. doi: 10.1016/j.humimm.2024.110765.
- Zhang X., Qin Y., Wan X., Liu H., Lv C., Ruan W., He L., Lu L., Guo X. Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities. J. Transl. Med., 2021, Vol. 19, no. 1, 62. doi: 10.1186/s12967-021-02727-3.
